Portfolio
Novexel SA was a specialty pharmaceutical company focused on the discovery and development of novel antibiotics and antifungal agents to overcome significant global problem of microbial drug resistance.
The company was formed in 2004 as the result of a spin-out of the anti-infectives unit of Aventis Pharma, a world-leader in the discovery and provision of antimicrobial drugs.
In 2009 Novexel SA was acquired by AstraZeneca for a total cash consideration of up to $505 million.
Status: Realised
Investment
NeoMed identified Novexel SA as an attractive investment opportunity in 2006 and had access to the oversubscribed Series B financing through personal contacts and network in the venture capital industry in Europe.
NeoMed was an observer board member and worked in collaboration with other investors to deliver a successful trade sale to AstraZeneca.
NeoMed sold its shares in this transaction in 2010.